Nucleic Acid Amplification Testing Market Analysis And Forecast To 2032: By Type (Polymerase Chain Reaction (PCR) tests, Isothermal Nucleic Acid Amplification Technology (INAAT) tests, Ligase Chain Reaction (LCR) tests), By Application (Infectious Disease

The global Nucleic Acid Amplification Testing Market was valued at USD 7.3 Billion in 2022 and it is anticipated to grow up to USD 24.5 Billion by 2032, at a CAGR of 12.8% during the forecast period.

A Nucleic Acid Amplification Test, or NAAT, is a type of viral diagnostic test for SARS-CoV-2, the virus that causes COVID-19. NAATs detect genetic material (nucleic acids). NAATs for SARS-CoV-2 specifically identify the RNA (ribonucleic acid) sequences that comprise the genetic material of the virus.

Market Trends and Drivers

Increase in demand for the advanced rapid diagnostics and rising R&D investments for the development of novel biotechnological diagnostic techniques are the factors fueling the market growth. In addition, high global prevalence of the communicable diseases and need for the highly efficient testing alternatives for the successful management of disease outbreaks has propelled demand for the several nucleic acid amplification testing technologies. Emerging infectious diseases, such as the Monkeypox virus, are opening new avenues for market growth and is evident by the launch and regulatory approval of nucleic acid amplification test products for such diseases. For instance, in September 2022, Quest Diagnostics received the U.S. FDA’s Emergency Use Authorization (EUA) for its Quest Monkeypox PCR test launched in July 2022. Similarly, in August 2022, Todos Medical Ltd. commercially launched its Monkey Pox PCR-based test in the U.S. Hence, such novel infections are expected to further expand the market growth.

Market Restraints and Challenges

There are several key restraints and challenges in the Nucleic Acid Amplification Testing market. First, encryption can be a complex and resource-intensive process, particularly for large banks with thousands of customers and transactions. Second, encryption can also be vulnerable to attack, and banks must constantly update and improve their encryption software to stay ahead of the latest threats. Finally, encryption can also impede the ability of law enforcement and other government agencies to access data for criminal investigations, which can be a major challenge in some cases.

The report analyses the global Nucleic Acid Amplification Testing Market based on type, application, end-use, and region.
Global Nucleic Acid Amplification Testing Market by Type
By type, the market is segmented into Polymerase Chain Reaction (PCR) tests, Isothermal Nucleic Acid Amplification Technology (INAAT) tests, and Ligase Chain Reaction (LCR) tests. The PCR tests segment recorded the largest market share of xx% in 2022. The technology enables rapid and sensitive detection of a broad range of target nucleic acid molecules and can be used for the detection of specific pathogens that may be difficult to culture in vitro. In addition, widespread penetration of PCR technology has enabled applications of the technique for the detection, quantification, and genotyping of a variety of bacteria and viruses from several types of clinical specimens, including plasma, serum, semen, cerebrospinal fluid, and others. As a result, the PCR tests segment is expected to witness significant growth during the forecast period.

The Isothermal Nucleic Acid Amplification Technology (INAAT) tests segment is projected to expand at a rapid CAGR during the forecast period due to the introduction of novel technologies, such as loop-mediated isothermal amplification (LAMP), strand displacement amplification, and recombinase polymerase amplification, among others, that are broadening the scope of the applications for nucleic acid-based test products. For instance, in June 2022, a research study published in the Analyst Journal demonstrated a new smartphone-integrated technology that can perform rapid Zika virus testing in a single blood drop with the help of the LAMP technology. Such advancements are anticipated to drive the segment and positively affect market growth.
Global Nucleic Acid Amplification Testing Market by Application
By application, the Nucleic Acid Amplification Testing Market is classified into Infectious Disease Testing, Oncology Testing, Genetic & mitochondrial disease testing, and Others. The infectious disease segment held the largest market share of xx% in 2021. This can be attributed to the widespread prevalence and rising incidence rate of infectious diseases such as influenza, sexually transmitted infections, and others. The COVID-19 testing sub-segment held the largest share in 2021 within the infectious disease testing segment due to the global presence of the pandemic and the launch of several new PCR tests. For instance, in October 2020, Euro fins Central Laboratory launched its Empower DX SARS CoV 2 RT PCR test with the option for at-home sampling. Such product launches are expected to increase the market penetration of PCR tests and drive segment growth.

Oncology testing segment is projected to expand at the fastest CAGR during the forecast period due to the rise in R&D interests for the development of novel cancer diagnostic alternatives and rapid progress in cancer research. For instance, in March 2022, researchers from Queen Mary University of London announced the development of the first PCR test for the detection of oral cancer. Such advancements are likely to fuel growth prospects for the nucleic acid amplification testing of other ontological conditions in the near future.
Global Nucleic Acid Amplification Testing Market by End-use
The end-use. Market is segmented ino Hospitals, Central and reference laboratories, and Others. The central and reference laboratories segment dominated the market in 2022 due to its extensive testing portfolio and coverage across multiple healthcare settings. In addition, supportive government initiatives are aiding in the expansion of the testing capacities of such laboratories. For instance, in June 2022, the Department of Health and Human Services (HHS) expanded the Monkeypox testing capacity to five laboratory companies, including Lab corp., Quest Diagnostics, Mayo Clinic Laboratories, Aegis Science, and Sonic Healthcare.

Hospitals segment is expected to grow at the fastest CAGR of xx% by 2032. The rise in healthcare expenditure globally and the increasing role of nucleic acid amplification techniques for disease surveillance and prevention of outbreaks are the factors leading to the growth of the segment. Similarly, growth in hospital testing capacities post-COVID-19 and availability of the high throughput testing capabilities can considerably boost the market prospects for nucleic acid amplification testing.

Geographical Analysis of Global Nucleic Acid Amplification Testing Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest revenue share of over 28.0% in 2021. North America accounted for the largest market share xx% in 2022 due to the high extent of chronic disease prevalence and the presence of an established research and healthcare infrastructure. Similarly, demand for nucleic acid amplification tests is also driven by the increasing focus on point-of-care diagnostic methods and the high extent of disease prevention measures in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period due to the existence of a large population and rising focus on the healthcare systems. High incidence of emerging infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections can strengthen the market prospects for nucleic acid amplification testing.

Major Players in the Global Nucleic Acid Amplification Testing Market

The key players in the Nucleic Acid Amplification Testing Market F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bio Mérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., See gene Inc., among others.

COVID-19 Impact:

The COVID-19 has increased demand for the rapid and accurate testing methods, such as nucleic acid amplification testing, for detection of the SARS-CoV-2 virus. Key players involved in the market have developed new product offerings, such as isothermal nucleic acid amplification technology-based tests, to meet high demand for the rapid testing and point-of-care testing. For instance, in March 2020, Abbott Laboratories received Emergency Use Authorization (EUA), for its Abbott ID NOW COVID-19 test which can deliver positive results within five minutes and negative results within 13 minutes. Such strategic initiatives fueled by the pandemic are expected to boost market growth in the near future.

Recent Developments:

• September 2022, Mylab Discovery Solutions debuted their Patho Detect HPV Identification PCR Test for the detection of human papillomavirus (HPV) in high-risk patients.
• Abingdon Health announced a new version of the successful NALFIA fast test in January 2019 for the detection of DIG/Biotin and/or FITC (Or FAM)/biotin-labeled analytes.
• In September 2018, researchers at the National University of Singapore created a portable platform for a point-of-care nucleic acid test that can be used to diagnose a variety of diseases. "enVision" is the name of the device (enzyme-assisted nanocomplexes for visual identification of nucleic acids).
• In September 2018, researchers at the National University of Singapore created a portable platform for a point-of-care nucleic acid test that can be used to diagnose a variety of diseases. "enVision" is the name of the device (enzyme-assisted nanocomplexes for visual identification of nucleic acids)

Frequently Asked Questions

Q1. How big is the biliary stents market?Ans. The global Nucleic Acid Amplification Testing Market was valued at USD 7.3 Billion in 2022 and it is anticipated to grow up to USD 24.5 Billion by 2032, at a CAGR of 12.8% during the forecast period.Q2. What is the Nucleic Acid Amplification Testing Market growth rate?Ans. The growth rate of the Nucleic Acid Amplification Testing Market is 12.8%Q3. Which region holds a major market share for the market?Ans. North America holds a major market share of the Nucleic Acid Amplification Testing Market in 2021.Q4. Which segment accounted for the largest Nucleic Acid Amplification Testing Market share?Ans. By End-use, the hospital segment accounted for the largest Nucleic Acid Amplification Testing Market share.Q5. Who are the key players in the kidney stones management market?Ans. The global Nucleic Acid Amplification Testing Market report includes players such as  F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bio Mérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., See gene Inc., among others.Q6. What are the factors driving the Nucleic Acid Amplification Testing Market growth?Ans. Increase in demand for the advanced rapid diagnostics and rising R&D investments for the development of novel biotechnological diagnostic techniques are the factors fueling the market growth.Q7. What are the key growth strategies of Nucleic Acid Amplification Testing Market players?Ans. The key growth strategies of Nucleic Acid Amplification Testing Market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Nucleic Acid Amplification Testing Market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Nucleic Acid Amplification Testing Market during the forecast period.


Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.